Journal of Commercial Biotechnology logo Palgrave Macmillan logo

Publisher: Palgrave Macmillan

Volume 11, Number 3, 1 April 2005
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

< previous issue | next issue > | all issues

Editorial: Is the UK NHS a good place to do clinical trials?
pp. 205-207(3)
Author: Steiner, Jan

Introduction to the debate: How much regulation do we want or need?
pp. 208-208(1)
Author: Burke, Derek

NGO war on biotechnology
pp. 209-222(14)
Authors: Miller, Henry I; Conko, Gregory

Plant biotechnology, the regulator and the consumer
pp. 222-227(6)
Author: Bainbridge, Janet

The latest orphan drug designations and the Commission Communication on Regulation (EC) 141/2000
pp. 228-238(11)
Author: Shah, Rashmi R

Corporate development in biotechnology in 2005
pp. 239-248(10)
Author: Williams, Alan

Distribution of data and unique material resources made with NIH funding
pp. 249-262(14)
Author: Rohrbaugh, Mark L

Amgen v TKT: Assessment of inventive concept is crucial for assessing infringement of biotechnology patents
pp. 263-270(8)
Author: Cook, William

The quest for generic biotechnology pharmaceuticals in the USA
pp. 271-274(4)
Authors: Kowalski, Thomas J; Fekete, Pamela; Yvon, Anne-Marie C

The DNA/RNA market to 2010
pp. 275-278(4)
Authors: Belsey, Mark; Pavlou, Alex K

Legal and regulatory update
pp. 279-288(10)
Authors: Wilkinson, John; Dorey, Frederick J

Financial accounts reports
pp. 289-291(3)
Author: Aaronson, Colin

< previous issue | next issue > | all issues

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A